Pivotal Phase III ZINFORO® (ceftaroline fosamil) CAP studies
The efficacy and tolerability of ZINFORO® (ceftaroline fosamil) monotherapy have been consistently demonstrated in 6 large, double-blind, Phase III, randomised controlled clinical trials: 3 involving adult patients with cSSTI and 3 involving patients with CAP.1-4
Header | ||
---|---|---|
Header | Header | Header |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Primary end point outcomes1
Clinical cure rates: FOCUS 1 and FOCUS 2
ZINFORO® (ceftaroline fosamil) 600 mg q12h demonstrated comparable efficacy versus ceftriaxone
1 g q24h in terms of clinical cure rates.
Primary end point outcomes2
Clinical cure rates: Asia CAP
ZINFORO® (ceftaroline fosamil) 600 mg q12h demonstrated superior efficacy versus ceftriaxone 2 g q24h in terms of clinical cure rates.
Non-inferiority was defined as a lower limit of the 95% CI ≥–10% for the between-group difference. If this was achieved, the protocol stated that superiority would be concluded if the lower limit of the 95% CI ≥0%.2 The safety profile of ZINFORO® (ceftaroline fosamil) was similar to that observed in the pooled Phase III CAP and cSSTI studies.2
CAP, community-acquired pneumonia; CE, clinically evaluable; CI, confidence interval; cSSTI, complicated skin and soft tissue infection; EOT, end of treatment; FOCUS, ceFtarOline Community-acquired pneUmonia trial vS ceftriaxone in hospitalized patients; ITT, intent-to-treat; IV, intravenous; LFU, late follow-up; ME, microbiologically evaluable; MITT, modified intent-to-treat; MITTE, modified intent-to-treat efficacy; mMITT, microbiologically modified intent-to-treat; PORT, Pneumonia Patient Outcomes Research Team; q12h, every 12 hours; q24h, every 24 hourly TOC, test-of-cure.
References:
Simple dosing with a flexible infusion time
Safety profile consistent with other cephalosporins
ZINFORO® in the treatment of CAP and cSSTI
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.